dc.date.accessioned | 2023-12-18T17:30:34Z | |
dc.date.available | 2023-12-18T17:30:34Z | |
dc.date.created | 2023-12-02T16:50:57Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Mikalsen, I.M. Breder, Sigurd Medhus, Asle Wilhelm Folseraas, Trine Aabakken, Lars Ånonsen, Kim Vidar . ERCP for the initial management of malignant biliary obstruction–real world data on 596 procedures. Scandinavian Journal of Gastroenterology. 2023 | |
dc.identifier.uri | http://hdl.handle.net/10852/106405 | |
dc.description.abstract | Aims
To evaluate outcomes of ERCP as first-line management in patients with malignant biliary obstruction (MBO) of all causes and stages, reflecting a real-life setting.
Methods
Retrospective observational study of patients with ERCP as the first-line management of MBO at Oslo University Hospital between 2015 and 2021. Primary outcome measure was a ≥ 50% decrease from the pre-procedural bilirubin within 30 days after ERCP. Secondary outcome measures were technical success of ERCP, complications and overall mortality.
Results
A total of 596 patients were included, median age 70 years. ASA score was ≥ III in 67% of patients. The most common cancers causing MBO were pancreatic cancer (52%), metastatic lesions (20%) and cholangiocarcinoma (16%). The primary outcome measure was achieved in 62% of patients. With endoscopic access, overall technical success was 80% with 85% for the distal extrahepatic group, 71% for the perihilar, 40% for the intrahepatic and 53% for multiple level MBOs. Reinterventions were performed in 27% of the patients. Complications occurred in 15% of the patients, including post-ERCP pancreatitis in 9%. Most complications were of minor/moderate severity (81%). Overall mortality was 33% within the first 90 days. Patients deceased by the end of the study period (83%) had median survival of 146 days (range 1–2,582 days).
Conclusions
ERCP has a high rate of clinical effect and technical success in the management of both distal extrahepatic and perihilar MBO. Our data indicate that ERCP is a valid option in the first-line management of MBO. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | ERCP for the initial management of malignant biliary obstruction–real world data on 596 procedures | |
dc.title.alternative | ENEngelskEnglishERCP for the initial management of malignant biliary obstruction–real world data on 596 procedures | |
dc.type | Journal article | |
dc.creator.author | Mikalsen, I.M. | |
dc.creator.author | Breder, Sigurd | |
dc.creator.author | Medhus, Asle Wilhelm | |
dc.creator.author | Folseraas, Trine | |
dc.creator.author | Aabakken, Lars | |
dc.creator.author | Ånonsen, Kim Vidar | |
cristin.unitcode | 185,53,48,12 | |
cristin.unitname | Avdeling for transplantasjonsmedisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2207792 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Scandinavian Journal of Gastroenterology&rft.volume=&rft.spage=&rft.date=2023 | |
dc.identifier.jtitle | Scandinavian Journal of Gastroenterology | |
dc.identifier.startpage | 1 | |
dc.identifier.endpage | 9 | |
dc.identifier.pagecount | 0 | |
dc.identifier.doi | https://doi.org/10.1080/00365521.2023.2282375 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0036-5521 | |
dc.type.version | PublishedVersion | |